KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $350198.0.

  • Inovio Pharmaceuticals' Depreciation & Amortization (CF) fell 1648.17% to $350198.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 1903.52%. This contributed to the annual value of $1.8 million for FY2024, which is 3134.09% down from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Depreciation & Amortization (CF) of $350198.0 as of Q3 2025, which was down 1648.17% from $356151.0 recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Depreciation & Amortization (CF) peaked at $945200.0 during Q4 2021, and registered a low of $350198.0 during Q3 2025.
  • In the last 5 years, Inovio Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $660697.0 in 2021 and averaged $644182.2.
  • In the last 5 years, Inovio Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 4066.71% in 2022 and then crashed by 3999.35% in 2024.
  • Inovio Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $945200.0 in 2021, then fell by 2.31% to $923328.0 in 2022, then tumbled by 38.3% to $569687.0 in 2023, then fell by 18.43% to $464674.0 in 2024, then decreased by 24.64% to $350198.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $350198.0 for Q3 2025, versus $356151.0 for Q2 2025 and $371367.0 for Q1 2025.